CompletedPhase 3NCT02728752
Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
Studying Dermatomyositis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Octapharma
- Principal Investigator
- Wolfgang FrenzelInternational Medical Director
- Intervention
- Octagam 10%(drug)
- Enrollment
- 95 enrolled
- Eligibility
- 18-79 years · All sexes
- Timeline
- 2017 – 2019
Study locations (30)
- Octapharma Research Site, Huntington Beach, California, United States
- Octapharma Research Site, Los Angeles, California, United States
- University of California -Irvine, Orange, California, United States
- Octapharma Research Site, Orlando, Florida, United States
- NeuroMedical Research Center, Panama City, Florida, United States
- Octapharma Research Site, Plantation, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Octapharma Research Site, Kansas City, Kansas, United States
- Octapharma Research Site, Ann Arbor, Michigan, United States
- Octapharma Research Site, Rochester, Minnesota, United States
- Octapharma Research Site, Great Neck, New York, United States
- Octapharma Research Site, Portland, Oregon, United States
- Octapharma Research Site, Pittsburgh, Pennsylvania, United States
- Stones River Dermatology, Murfreesboro, Tennessee, United States
- Austin Neuromuscular Center, Austin, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02728752 on ClinicalTrials.govOther trials for Dermatomyositis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07111065FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)National Institute of Environmental Health Sciences (NIEHS)
- ACTIVE NOT RECRUITINGNCT07531446Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical ParametersRuijin Hospital
- RECRUITINGPHASE2, PHASE3NCT07160205Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)Restem, LLC.
- RECRUITINGNANCT07377058RCT of Tocilizumab for Anti-MDA5+DMPeking Union Medical College Hospital
- RECRUITINGNCT07345949Panniculitis in DermatomyositisUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE2NCT06857240Topical Ruxolitinib Cream for Refractory Cutaneous DermatomyositisThe Cleveland Clinic
- RECRUITINGPHASE1NCT06919380Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy TrialLi Shiyue
- RECRUITINGPHASE2NCT06672822Intralesional Injection of STS in Treatment of CalcinosisRobyn T. Domsic, MD, MPH